Company Overview and News
OVERLAND PARK, Kan., July 10, 2018 (GLOBE NEWSWIRE) -- YRC Worldwide Inc. (NASDAQ:YRCW) today announced that on Thursday, August 2, 2018, at 9:30 a.m. ET, company executives will host a conference call with the investment community to discuss second quarter 2018 financial results. The financial results will be released the same day, August 2, 2018, before the market opens.
OVERLAND PARK, Kan., June 11, 2018 (GLOBE NEWSWIRE) -- YRC Worldwide Inc. (NASDAQ:YRCW) reported certain operating metrics for the first two months of second quarter 2018.
This month is on track for the best May since 2009, disproving the old adage “Sell in May and Go Away.” Although political and geopolitical worries continue to weigh on markets, power-packed earnings, rise in oil price and easing U.S.-china trade fears have lead to a rally. Below we discuss some of the events that dominated the headlines in May and influenced the stock market: Power-Packed Earnings About 94.
8306 MUFG HEAR MBFJF YRCW MTU CEO
OVERLAND PARK, Kan., May 29, 2018 (GLOBE NEWSWIRE) -- YRC Worldwide Inc. (NASDAQ:YRCW) today announced that Darren Hawkins, chief executive officer and Stephanie Fisher, chief financial officer, will deliver a company presentation at 12:20 p.m. ET on Thursday, June 7, 2018, at the Deutsche Bank 9th Annual Global Industrials and Materials Summit in Chicago, Illinois.
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
The Kansas-headquartered premiere road transportation (JBHT) company, YRC Worldwide (YRCW), announced its 1Q18 earnings today. The company’s adjusted loss per share stood at $0.44, far better than Thomson Reuters–surveyed analysts’ estimate of a $0.71 loss per share. So the leading US trucker (XPO) beat analysts’ loss per share estimates by a huge margin of 38.2% in the first quarter of 2018.
Document Table of Contents UNITED STATES
OVERLAND PARK, Kan., May 03, 2018 (GLOBE NEWSWIRE) -- YRC Worldwide Inc. (NASDAQ:YRCW) reported consolidated operating revenue for first quarter 2018 of $1.215 billion and a consolidated operating loss of $4.3 million, which included a $3.2 million loss on property disposals. As a comparison, for the first quarter 2017, the Company’s results included operating revenue of $1.171 billion and consolidated operating income of $0.
OVERLAND PARK, Kan., May 01, 2018 (GLOBE NEWSWIRE) -- YRC Freight has been named for the fourth time as the National Shippers Strategic Transportation Council’s (NASSTRAC)- National LTL Carrier of the Year. Through its annual Carrier of the Year Awards Program, NASSTRAC recognizes carriers that have demonstrated excellence in transportation, while also helping shippers identify the best of the best in carrier performance and value.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET